Employees: 2,170
Size Beijing Bohui Innovation Biotechnology (300318.SZ) is a China Health Care company (Biotechnology) with a market value of $518M, the 3611th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥4.29 on 18 Nov 2026.
Performance Over six months the shares fell 19.5%, against -12.9% for the median peer and -20.0% for the China market (cap-weighted) — 8th lowest of 19 in its peer set.
Growth Revenue fell 1.5% over the last twelve months (peer median +3.1%); the operating margin is -13.1% (peer median -15.6%).
Valuation It trades at 6.2× enterprise value to sales against a peer median of 6.3× (7th cheapest of 15).
Capital Return on invested capital runs 5.5 points below its cost of capital (5.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥822M | CN¥820M | CN¥848M | CN¥1.04B | CN¥792M |
| Revenue growth | — | -3% | -19% | +31% | — |
| Gross profit | CN¥330M | CN¥269M | CN¥350M | CN¥379M | CN¥174M |
| EBITDA | n/a | CN¥69.3M | CN¥173M | CN¥175M | CN¥14.2M |
| Net income | -CN¥82.9M | -CN¥91.9M | CN¥9.25M | -CN¥24.9M | -CN¥78.4M |
| Free cash flow | -CN¥210M | -CN¥292M | -CN¥227M | -CN¥60.5M | -CN¥121M |
| Capital expenditure | CN¥110M | CN¥157M | CN¥189M | CN¥198M | CN¥161M |
| Total debt | CN¥908M | CN¥1.13B | CN¥1.06B | CN¥814M | CN¥794M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300318.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -10.4% | -12.0% | 11th highest of 21 |
| 6-month return | -19.5% | -12.9% | 8th lowest of 19 |
| Distance from 52-week high | -50.3% | -46.4% | 9th lowest of 21 |
| Revenue growth (TTM) | -1.5% | +3.1% | 7th lowest of 15 |
| Operating margin | -13.1% | -15.6% | 8th highest of 15 |
| EV / Sales | 6.2× | 6.3× | 7th cheapest of 15 |
| ROIC minus cost of capital | -5.5 pp | -3.8 pp | 5th lowest of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Beijing Bohui Innovation Biotechnology 300318.SZ | China | $518M | -20% | -1% | -13% | 6.2× | n/a | n/a |
| LongBio Pharma (Suzhou) 1779.HK | Hong Kong | $510M | n/a | n/a | n/a | n/a | n/a | n/a |
| Valneva VLA.PA | France | $508M | -6% | -27% | -87% | 3.9× | n/a | n/a |
| Beijing Scitop Bio-Tech 300858.SZ | China | $501M | -28% | +4% | 8% | 7.5× | n/a | n/a |
| Frontage 1521.HK | Hong Kong | $542M | +113% | +10% | 8% | 2.3× | 14.3% | +15.4% |
| Sinotherapeutics 688247.SS | China | $494M | -19% | -17% | 0% | 6.2× | 29.4% | +7.0% |
| Climb Bio CLYM | United States | $546M | -12% | n/a | n/a | n/a | n/a | n/a |
| Wave Life Sciences WVE | United States | $546M | -55% | -35% | -321% | 2.2× | n/a | n/a |
| Liaoning Dingjide Petrochemical 603255.SS | China | $490M | -24% | +70% | 5% | 5.2× | n/a | n/a |
| CHO Pharma 6586.TWO | Taiwan | $488M | +24% | -47% | -17,694% | 8,281.1× | n/a | n/a |
| Hvsen Biotechnology 300871.SZ | China | $553M | -22% | +2% | 17% | 2.3× | n/a | n/a |
| Sana Biotechnology SANA | United States | $554M | -41% | n/a | n/a | n/a | n/a | n/a |
| Crescent Biopharma CBIO | United States | $482M | -34% | n/a | -1,217% | 13.3× | n/a | n/a |
| TaiMed Biologics 4147.TWO | Taiwan | $480M | +19% | +7% | -31% | 22.7× | n/a | n/a |
| Monopar Therapeutics MNPR | United States | $479M | +9% | n/a | n/a | n/a | n/a | n/a |
| Neurogene NGNE | United States | $479M | -14% | -100% | n/a | n/a | n/a | n/a |
| Boji Medical Technology 300404.SZ | China | $561M | -6% | +32% | 4% | 3.4× | 31.9% | +27.2% |
| Genfit GNFT.PA | France | $571M | +22% | +28% | -130% | 11.0× | 39.8% | +143.5% |
| Ascletis Pharma 1672.HK | Hong Kong | $571M | -72% | -59% | -71,976% | 1,794.8× | n/a | n/a |
| Fennec Pharmaceuticals FENC | United States | $471M | +37% | +71% | 5% | 6.4× | 58.8% | +204.7% |
| TenNor Therapeutics Suzhou 6872.HK | Hong Kong | $470M | n/a | n/a | n/a | n/a | n/a | n/a |